DIS vs PFE: Which Is the Better Buy?
Side-by-side comparison of The Walt Disney Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
The Walt Disney Company · Communication Services
$103.89
+45.0% upside to fair value
Grade B
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
DIS has more upside to fair value
(+45.0%).
DIS trades at a lower forward P/E
(16.6x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DIS |
PFE |
| Current Price |
$103.89 |
$25.22 |
| Fair Value Estimate |
$150.64 |
$25.92 |
| Upside to Fair Value |
+45.0%
|
+2.8%
|
| Market Cap |
$180.4B |
$143.7B |
| Forward P/E |
16.6x
|
19.2x
|
| EV / EBITDA |
11.4x
|
12.3x
|
| Price / Sales |
1.9x
|
2.3x
|
| Price / FCF |
25.4x
|
15.2x
|
| Revenue Growth YoY |
+6.5%
|
+5.4%
|
| Gross Margin |
37.2%
|
69.3%
|
| Operating Margin |
15.5%
|
23.4%
|
| Return on Equity |
10.3%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
3.94%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
The Walt Disney Company operates as a diversified entertainment conglomerate with strong positions in media networks, parks and experiences, and sports. The company benefits from a durable competitive moat driven by its iconic brand, extensive content library, and integrated ecosystem spanning streaming, theatrical, and physical experiences. Despite a 31.4% decline in earnings in the most recent …
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
DIS |
PFE |
| Zone Low |
$112.98 |
$19.44 |
| Zone High |
$128.04 |
$22.03 |
| In Buy Zone? |
Yes
|
No
|